yahoo_financeOriginal article
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
Data ReadoutpositivePOMBILITIOPFOLDAPositive
AI Analysis
Summary
BioMarin announced five-year Phase 3 data for POMBILITI (cipaglucosidase alfa-atga) plus OPFOLDA (miglustat) combination therapy presented at the World Muscle Society Annual Congress. The long-term efficacy data represents a significant milestone for the Pompe disease treatment regimen.
Clinical Trial Data
Phase
3
Outcome Details
Five-year Phase 3 data presented
Importance:6/10
Sentiment:
0.60
Phase 3Data ReadoutCombination TherapyPompe Disease
Related Companies
Read the original article
Published by yahoo_finance on October 2, 2026 3:00 PM